Drug Profile
Research programme: insulin controlled release - SmartCells
Alternative Names: SmartInsulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Massachusetts Institute of Technology
- Developer SmartCells
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (SC, Injection)
- 04 Dec 2010 This programme is still in active development
- 29 Oct 2008 Preclinical trials in Type-1 diabetes mellitus in USA (SC)